The lack of pharmacological C/EBPδ‐targeting compounds does, however, obscure preclinical assessment of C/EBPδ as treatment modality in cancer, and consequently, we here set out a high‐throughput screen to identify small molecules that may either inhibit or enhance C/EBPδ activity. Here, CEBPD is linked to cancer.